Tiziana Life Sciences

Historical price data

Tiziana Life Sciences is focused on developing breakthrough immunotherapies, primarily through intranasal delivery, to treat debilitating neurodegenerative conditions. Its core technology centers on foralumab, the only fully human anti-CD3 monoclonal antibody, which is in multiple Phase 2 trials for na-SPMS, Multiple System Atrophy, Alzheimer's, and ALS, with promising biomarker data recently reported. The company's strategy leverages a patent-protected platform until 2040 and is supported by grants and direct financings, positioning it to address significant unmet medical needs in neurology.

Development of fully human monoclonal antibodies, with a focus on the intranasal delivery of foralumab (anti-CD3 mAb) to achieve targeted immunomodulation in the central nervous system for neurodegenerative diseases.

14 drugs in pipeline

Total raised: $20M

Faces competition from large pharma (e.g., Biogen, Eisai, Lilly in Alzheimer's; Novartis in MS) and other biotechs developing neuroimmunology therapies. Primary differentiation is its unique fully human anti-CD3 monoclonal antibody and intranasal delivery route, aiming for targeted CNS modulation with a favorable safety profile. Its niche focus on 'non-active' SPMS and PIRA progression addresses a specific subpopulation with limited treatment options.